Fax: (626) 856-5853
Effects of weekly paclitaxel or paclitaxel plus carboplatin on functionality and symptoms of geriatric patients with cancer as measured by a brief geriatric oncology module†
A pilot experience
Article first published online: 17 MAY 2005
Copyright © 2005 American Cancer Society
Volume 103, Issue 12, pages 2623–2628, 15 June 2005
How to Cite
Presant, C. A., Thompson, E., LeBerthon, B., Vergara, L. and McGowen, P. (2005), Effects of weekly paclitaxel or paclitaxel plus carboplatin on functionality and symptoms of geriatric patients with cancer as measured by a brief geriatric oncology module. Cancer, 103: 2623–2628. doi: 10.1002/cncr.21090
Presented, in part, to the American Society of Clinical Oncology, Chicago, IL, June 9, 2003.
- Issue published online: 2 JUN 2005
- Article first published online: 17 MAY 2005
- Manuscript Accepted: 2 FEB 2005
- Manuscript Revised: 23 DEC 2004
- Manuscript Received: 22 OCT 2004
- Bristol Meyers-Squibb
- geriatric oncology;
- quality of life;
- elderly patients
To measure functionality, symptoms, and quality of life in elderly patients, a geriatric oncology module (GOM) was developed that could be rapidly and effectively administered in community oncology practices.
The GOM was validated by semi structured patient interviews. The authors tested 26 patients receiving chemotherapy with paclitaxel or paclitaxel plus carboplatin to determine the effect of drug treatment on functionality, symptoms, and quality of life (QOL).
Chemotherapy stabilized or improved functionality, symptoms, and QOL in 75%, 86%, and 76% of patients, respectively. This GOM was easily implemented in a busy community oncology practice.
Weekly paclitaxel and paclitaxel plus carboplatin produced measurable palliation in geriatric oncology patients. This GOM may be useful in the assessment of specific chemotherapeutic interventions in elderly patients with cancer in community oncology practices. Cancer 2005. © 2005 American Cancer Society.